Business
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
About this update from Idexx Laboratories, Inc.
[{"type":"text","content":"\nBuilt-in SDMA delivers earlier insights with seamless workflow\n\n\n WESTBROOK, Maine--(BUSINESS WIRE)--\nIDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that SDMA, a renal biomarker, will be built into Catalyst™ CLIPs, making complete kidney function evaluation part of the most common point-of-care chemistry profiles. Available beginning in June to customers in the United States and Canada, the integration expands access to advanced kidney assessment at scale, enabling veterinarians to identify kidney function loss earlier and act sooner, without disrupting familiar workflows.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519642899/en/Catalyst SDMA Testing\nSupported by peer-reviewed studies using the IDEXX SDMA™ Test, SDMA is recognized by the International Renal Interest Society (IRIS) as a key biomarker for evaluating kidney function in pets.1 Since introducing the IDEXX SDMA™ Test in 2015, IDEXX has performed approximately 119 million SDMA patient tests globally primarily through its reference laboratories and increasingly on the Catalyst platform,2 underscoring the test’s clinical importance and broad adoption in kidney health evaluation. Results are seamlessly integrated into VetConnect™ PLUS, alongside other diagnostic data.\n\n\n“SDMA is a clear example of how IDEXX innovates by developing clinically relevant diagnostics and then scaling their impact through platforms veterinarians already use every day,” said Mike Erickson, President and CEO of IDEXX. “Earlier insight enables earlier action, improving outcomes for pets, strengthening care experiences, and supporting durable, long-term growth for veterinary practices and IDEXX.”\n\n\nChronic kidney disease (CKD) is common in dogs and cats and frequently unrecognized, particularly early in the disease. Clinical evidence continues to show that including SDMA in routine diagnostic testing enables earlier detection of meaningful declines in kidney function that conventional markers alone may miss.3–6 In addition, a study, published in the Journal of the American Veterinary Medical Association, found that cats with early-stage CKD treated with a renal diet experienced slower disease progression and improved survival.7\n\n\n“Kidney disease is common in...